Page last updated: 2024-09-05

sorafenib and hispidulin

sorafenib has been researched along with hispidulin in 1 studies

Compound Research Comparison

Studies
(sorafenib)
Trials
(sorafenib)
Recent Studies (post-2010)
(sorafenib)
Studies
(hispidulin)
Trials
(hispidulin)
Recent Studies (post-2010) (hispidulin)
6,5207305,251123076

Protein Interaction Comparison

ProteinTaxonomysorafenib (IC50)hispidulin (IC50)
nuclear receptor subfamily 0 group B member 1Homo sapiens (human)0.8337
Serine/threonine-protein kinase pim-1Homo sapiens (human)2.71
Dipeptidyl peptidase 4Sus scrofa (pig)0.49
Receptor-type tyrosine-protein kinase FLT3Homo sapiens (human)0.3533
MAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)1.205
MAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)0.252

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Chen, LC; Hsu, KC; Huang, HL; Huang, WJ; Lien, ST; Lin, TE; Ngo, ST; Pan, SL; Sung, TY; Tseng, HJ; Wu, YW; Yen, SC1

Other Studies

1 other study(ies) available for sorafenib and hispidulin

ArticleYear
Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia.
    Journal of natural products, 2021, 01-22, Volume: 84, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Flavonoids; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Xenograft Model Antitumor Assays

2021